Condition
Diabetes Mellitus, Type 1
Locations
Germany
Start date
01/07/2025
Identifiers
Trial ID NN6497-8316,
NCT number NCT07087795,
Eudract number Not Available
NCT number NCT07087795,
Eudract number Not Available
Summary
This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.
Trial Overview:
Treatment
DRUG: NNC0194-0499
DRUG: Placebo
DRUG: Semaglutide
Study type
INTERVENTIONAL
Trial duration
Jul 01 2025 - Sep 25 2026
Participants
96
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 64 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.